Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
We are interested to read that the subjects of the Northwick Park
drug trial may receive large sums of compensation. However, the
volunteers in this trial are not alone in incurring substantial costs.
The NHS and in particular Northwick Park Hospital, have incurred the
considerable costs of intensive care and other in-hospital treatment.
TeGenero who made the drug and Parexel who conducted the trial have
benefited, whether deliberately or not, from a kind of NHS insurance
against the medical risk of this experimental drug in their trial
participants. TeGenero or Parexel should offer to pay the costs of
hospital treatment for these subjects.
NHS costs of trial drug reactions
We are interested to read that the subjects of the Northwick Park
drug trial may receive large sums of compensation. However, the
volunteers in this trial are not alone in incurring substantial costs.
The NHS and in particular Northwick Park Hospital, have incurred the
considerable costs of intensive care and other in-hospital treatment.
TeGenero who made the drug and Parexel who conducted the trial have
benefited, whether deliberately or not, from a kind of NHS insurance
against the medical risk of this experimental drug in their trial
participants. TeGenero or Parexel should offer to pay the costs of
hospital treatment for these subjects.
Competing interests:
None declared
Competing interests: No competing interests